Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Dalbavancin; Teicoplanin

Criteria

Inclusion Criteria:

• 12 to 17 year old adolescents hospitalized for the treatment of bacterial infections.

Exclusion Criteria:

• Patients being treated with vancomycin.

• Patients with liver and kidney failure.

• Pregnant female subjects.